Glioblastoma has a long-term survival rate under 1% at ten years. After decades of research focusing primarily on mutation-targeted therapies, median survival has improved by only a few months. Dr. Tomás Duraj believes there's a better path forward. Dr. Duraj is a physician-scientist at Boston College working on the metabolic vulnerabilities of cancer. In this Metabolic Health Summit presentation, he outlines a clinical framework for studying ketogenic metabolic therapy — one built on biomark...